Safe Harbor Site Integration for Predictable Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for integrating and expressing genes in human cells face safety concerns due to random viral-mediated integration and unpredictable gene expression patterns, limiting their clinical and industrial applications.
Innovation Solution
Identification and validation of novel genomic safe harbor sites in the human genome for targeted and stable expression of genes, using bioinformatic searches and CRISPR/Cas9 genome editing to integrate reporter and therapeutic genes without disrupting cellular functions, and the use of engineered nucleic acid targeting vectors with homology arms flanked by safe harbor site sequences.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If random viral-mediated integration is used for gene integration, then the integration process is simple and efficient, but the safety and predictability of gene expression is compromised
Solution Approach 1:
The patent segments the genome into potential safe harbor sites (identified through bioinformatic analysis of chromatin accessibility, transcription factor binding, and gene density) and uses CRISPR/Cas9 to target specific segments rather than allowing random integration. This segmentation enables predictable integration while maintaining efficiency through targeted delivery.
Solution Approach 2:
The patent employs CRISPR/Cas9 as an intermediary mechanism between the gene of interest and the genome. The Cas9 enzyme, guided by RNA molecules, mediates precise integration at predetermined safe harbor sites, replacing the random viral integration process with a controlled, predictable mechanism that ensures both safety and expressibility.
2Reliability
If targeted genomic integration at existing sites is used, then expression predictability improves, but safety concerns arise from disruption of cellular functions
Solution Approach 1:
The patent applies local quality by identifying and selecting specific genomic locations (safe harbor sites) that have unique properties: open chromatin structure, high transcription factor binding, low gene density, and absence of repetitive elements. These localized regions are optimized to accept integrated genes without disrupting surrounding cellular functions, thus achieving both predictability and safety.
Solution Approach 2:
The patent performs preliminary bioinformatic analysis and validation before actual integration to identify suitable safe harbor sites. By pre-screening for chromatin accessibility, transcription factor occupancy, and genomic context, the method ensures that integration occurs only at sites proven to be safe and predictable, preventing cellular function disruption before it can occur.
3Adaptability or versatility
If novel safe harbor sites are identified through bioinformatic search, then the number of available integration sites increases, but validation complexity increases
Solution Approach 1:
The patent applies partial action by validating a subset of bioinformatically predicted sites through experimental methods (CRISPR/Cas9 integration followed by phenotypic analysis and transcriptome sequencing). Rather than validating all predicted sites exhaustively, the method identifies and characterizes a representative set of safe harbor sites that demonstrate the required properties, providing sufficient versatility while managing validation complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables predictable and safe long-term expression of genes in various cell types, enhancing genome engineering safety and efficacy for therapeutic and biomanufacturing applications, such as cancer therapy and protein production.
Implementation Method 1
using bioinformatic searches and CRISPR/Cas9 genome editing to integrate reporter and therapeutic genes without disrupting cellular functions
Implementation Method 2
engineered nucleic acid targeting vectors with homology arms flanked by safe harbor site sequences
Data Source
AI summary
Provided herein, in some embodiments, are engineered nucleic acid targeting vectors that include a sequence of interest flanked by homology arms, each homology arm comprising a sequence homologous to a sequence in a safe harbor site in the human genome in any one of the following loci: 1q31, 3p24, 7q35, and Xq21. Also provided herein are methods of using and compositions the comprising engineered nucleic acid targeting vectors.